Bifogade filer
Beskrivning
Land | Danmark |
---|---|
Lista | Spotlight DK |
Sektor | Hälsovård |
Industri | Medicinteknik |
Copenhagen, Denmark, 17 November 2022 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company at SEB Healthcare Seminar 2022 (https://eur05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fseb.evitbe.com%2FHealthcareSeminar&data=05%7C01%7C%7Cf1a6bd8cf58349a76df408dac68451d7%7Ca8e2696403b34b1da4035bf4413d0a1c%7C0%7C0%7C638040568867748164%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=zzZZaGOP3kOmAAXqfBuWvadj%2Bx6vsfOMMFDrSH1ja9g%3D&reserved=0), 21 November 2022.
The presentation will include an update on the momentum and business progress made by the company during 2022 and look ahead at the coming news flow for rest of the year. Management will give an overall update on the company's pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain and prostate cancer as well as Neuroendocrine and head & neck cancer.
The presentation will be webcasted live 13:05-13:35 (CET), Monday 21 November 2022.